Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Rule 8.3-Angle Plc

12 May 2008 13:20

RNS Number : 2093U
Kaupthing Bank hf
12 May 2008
 
FORM 8.3
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE
(Rule 8.3 of the Takeover Code)
 
 
1. KEY INFORMATION
 
Name of person dealing (Note 1)
Kaupthing Bank hf
Company dealt in
Angle Plc
Class of relevant security to which the dealings being disclosed relate(Note 2)
Ordinary Shares
Date of dealing
09 May 2008
 
 
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
 
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
 
 
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
 
9,418 (0.03%)
(2) Derivatives (other than options)
 
1,017,125 (3.75 %)
 
1,017,125 (3.75 %)
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
1,017,707 (3.75 %)
 
1,026,543 (3.78 %)
 
 
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
 
Class of relevant security:
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
 
 
(2) Derivatives (other than options)
 
 
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
 
 
 
(c) Rights to subscribe (Note 3)
 
Class of relevant security:
 
Details
 
 
 
 
 
3. DEALINGS (Note 4)
 
(a) Purchases and sales 
 
Purchase/sale
 
Number of securities
Price per unit (Note 5)
Sell
10,000
39.50p
 
 
 
 (b) Derivatives transactions (other than options)
 
Product name,
e.g. CFD
Long/short (Note 6)
Number of securities (Note 7)
Price per unit (Note 5)
 
 
 
 
 
 
 
 
 
 
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
 
Product name,
e.g. call option
 
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise
price
Type, e.g. American, European etc.
Expiry
date
Option money
paid/received per unit (Note 5)
 
 
 
 
 
 
 
 
 
 
 
 
(ii) Exercising
 
Product name, e.g. call option
Number of securities
Exercise price per unit (Note 5)
 
 
 
 
 
 
(d) Other dealings (including new securities) (Note 4)
 
Nature of transaction (Note 8)
 
Details
Price per unit (if applicable)(Note 5)
 
 
 
 
 
 
4. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. 
No voting rights on CFD holdings
 
 
 
Is a Supplemental Form 8 attached? (Note 9) NO
 
 
Date of disclosure
12 May 2008
Contact name
Richard Easton
Telephone number
0203 205 6620
If a connected EFM, name of offeree/offeror with which connected
 
If a connected EFM, state nature of connection (Note 10)
 
 
 
Notes
 
The Notes on Form 8.3 can be viewed on the Takeover Panel’s website at www.thetakeoverpanel.org.uk
 
 
This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETXLLFFVEBFBBD
Date   Source Headline
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.